. Prolactin inhibitor that acts by direct stimulation of the D2-dopamine receptors on pituitary lactotrophs, thus inhibiting prolactin secretion.
. Has a potent and long-lasting prolactin-lowering activity.
. Indicated for inhibition/suppression of physiological lactation & treatment of hyperprolactinaemic disorders.
. 84% of patients had normal serum prolactin levels after cabergoline treatment at doses 1 – 2 mg/ week.
. 90% showing disappearance of Galactorrhea.
. 50 – 90% reduction in tumor size in female and male patients with micro- or macroprolactinoma.